Anaplastic lymphoma kinase (ALK) inhibitors for oncogenic ALK gene rearranged non-small cell lung cancer (NSCLC), noted in 3.6–4.4 % of patients with NSCLC [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.